Stockscreener 앱 받기
1.58
3.27%
0.05
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
Cardiol Therapeutics (FRA:CT9) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics - The Deep Dive
HC Wainwright Issues Optimistic Estimate for CRDL Earnings - Defense World
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
What is HC Wainwright's Forecast for CRDL FY2024 Earnings? - MarketBeat
Equities Analysts Set Expectations for CRDL FY2024 Earnings - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Up 1.8%What's Next? - MarketBeat
Leede Financial Issues Positive Forecast for CRDL Earnings - Defense World
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug - openPR
What is Leede Financial’s Estimate for CRDL FY2027 Earnings? - Defense World
What is Leede Financial's Forecast for CRDL FY2024 Earnings? - MarketBeat
Roth Capital Has Negative Outlook for CRDL FY2024 Earnings - MarketBeat
Biotech Initiates Phase III Trial for Heart Disease Drug - Streetwise Reports
Pericarditis Drugs Market Is Expected To Reach $816.6 Million - openPR
Cardiol Therapeutics (NASDAQ:CRDL) Given Buy Rating at HC Wainwright - MarketBeat
What is Leede Financial's Forecast for CRDL FY2027 Earnings? - MarketBeat
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga
Analyst Says Biotech's Data Supports Advancement Into Phase III - Streetwise Reports
Five Top Heart Health Stocks to Buy Heading into 2025 - Baystreet.ca
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - openPR
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy - Proactive Investors USA
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
Cardiol's CardiolRx Shows Major Pain Relief Success in Phase II Pericarditis Trial | CRDL Stock News - StockTitan
Cardiol Therapeutics Faces Rising Losses and Falling Assets - TipRanks
Wealth Enhancement Advisory Services LLC Takes $27,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
"Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors" - WICZ
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors” - The Globe and Mail
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - Investing News Network
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Down 3.9% – Here’s What Happened - Defense World
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN - The Globe and Mail
Biotech and Technology Giants Drive Innovation Across Pharma, Me - WICZ
Cardiol Therapeutics (TSX:CRDL) Shares Outstanding (EOP) : 69.32 Mil (As of Jun. 2024) - GuruFocus.com
MMCAP International Inc. SPC Acquires Shares in Cardiol Therapeu - GuruFocus.com
Comparing Cardiol Therapeutics (NASDAQ:CRDL) and IN8bio (NASDAQ:INAB) - Defense World
Net Present Value Model: Cardiol Therapeutics Inc’s Cannabidiol 1 - GlobalData
Top 4 Canadian Biotech Stocks of 2024 - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Shares Down 0.8% – Should You Sell? - Defense World
Cardiol Therapeutics (TSE:CRDL) Trading Down 0.8%Should You Sell? - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Increase in Short Interest - MarketBeat
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
HC Wainwright Issues Negative Outlook for CRDL Earnings - Defense World
Equities Analysts Set Expectations for CRDL Q3 Earnings - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Shares Acquired by Foundations Investment Advisors LLC - Defense World
HC Wainwright Reiterates "Buy" Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
H.C. Wainwright maintains Buy rating on Cardiol Therapeutics shares By Investing.com - Investing.com UK
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? - MSN
Cardiol Therapeutics advances CardiolRx in new trial By Investing.com - Investing.com Australia
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX - openPR
Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx Trademark - openPR
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside… - Barchart
Cardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trial - Proactive Investors Australia
Cardiol Therapeutics advances CardiolRx in new trial - Investing.com
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Newsfile
Troutman Pepper Advises Cardiol Therapeutics in Closing of Over-Allotment Option - Troutman Pepper
BPH Global Ltd (ASX: BP8) – Trading Halt - Investing News Network
0.83%
1.03%
자본화:
|
볼륨(24시간):